CYCLOPHOSPHAMIDE, YTB323, FLUDARABINE PHOSPHATE, TOCILIZUMAB, RITUXIMAB, RITUXIMAB
CYTB323K12201
Phase 2 small_molecule active
Quick answer
CYCLOPHOSPHAMIDE, YTB323, FLUDARABINE PHOSPHATE, TOCILIZUMAB, RITUXIMAB, RITUXIMAB for Diffuse cutaneous systemic sclerosis (dcSSc) is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Diffuse cutaneous systemic sclerosis (dcSSc)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active